WO2023012278 - METHOD FOR DETERMINATION OF HYPERPHOSPHORYLATED TAU IN HUMAN CEREBROSPINAL FLUID BY LC-MS
National phase entry:
Publication Number
WO/2023/012278
Publication Date
09.02.2023
International Application No.
PCT/EP2022/071958
International Filing Date
04.08.2022
Title **
[English]
METHOD FOR DETERMINATION OF HYPERPHOSPHORYLATED TAU IN HUMAN CEREBROSPINAL FLUID BY LC-MS
[French]
PROCÉDÉ DE DÉTERMINATION DE PROTÉINE TAU HYPERPHOSPHORYLÉE DANS UN LIQUIDE CÉPHALO-RACHIDIEN HUMAIN PAR LC-MS
Applicants **
H. LUNDBECK A/S
Ottiliavej 9
2500 Valby, DK
Inventors
JACOBSEN, Anne-Marie
c/o H. Lundbeck A/S, Ottiliavej 9
2500 Valby, DK
OLSEN, Line, Rørbæk
c/o H. Lundbeck A/S, Ottiliavej 9
2500 Valby, DK
MERBEL, Nico, van de
c/o H. Lundbeck A/S, Ottiliavej 9
2500 Valby, DK
SCHALK, Frank
c/o H. Lundbeck A/S, Ottiliavej 9
2500 Valby, DK
Priority Data
21190078.2
06.08.2021
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
EPO
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 1030 | |
| EPO | Filing, Examination | 4601 | |
| Japan | Filing | 591 | |
| South Korea | Filing | 575 | |
| USA | Filing, Examination | 2710 |
Total: 9507 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention relates to a method of measuring pS396 Tau in a sample comprising the steps of i-iv, i) Treating a CSF sample from a subject suffering or suspected to be suffering from a Tau pathology with trypsin, ii) Subjecting the sample in step i) to a desphosphorylation agent and subsequently take part of the sample aside for step iv) before proceeding to step iii) with the remaining sample, iii) Subjecting the dephosphorylated sample from step ii) to a second trypsin treatment, iv) Measuring the amount of the Tau peptides (SPVVSGDTSPR) corresponding to Tau residues 396-406 in the samples from step ii) and step iii) using LC-MS.[French]
La présente invention concerne un procédé de mesure de pS396 Tau dans un échantillon comprenant les étapes i à iv consistant à : i) traiter un échantillon de CSF provenant d'un sujet atteint de manière avérée ou suspectée d'une pathologie Tau avec de la trypsine, ii) soumettre l'échantillon de l'étape i) à un agent de déphosphorylation et mettre une partie de l'échantillon de côté pour l'étape iv) avant de passer à l'étape iii) avec l'échantillon restant, iii) soumettre l'échantillon déphosphorylé de l'étape ii) à un deuxième traitement à la trypsine, iv) mesurer la quantité des peptides Tau (SPVVSGDTSPR) correspondant aux résidus Tau 396-406 dans les échantillons de l'étape ii) et de l'étape iii) par LC-MS